HUP0400698A2 - Csökkentett immunogenitású módosított interleukin-1-receptor-antagonista (IL-1RA) - Google Patents

Csökkentett immunogenitású módosított interleukin-1-receptor-antagonista (IL-1RA)

Info

Publication number
HUP0400698A2
HUP0400698A2 HU0400698A HUP0400698A HUP0400698A2 HU P0400698 A2 HUP0400698 A2 HU P0400698A2 HU 0400698 A HU0400698 A HU 0400698A HU P0400698 A HUP0400698 A HU P0400698A HU P0400698 A2 HUP0400698 A2 HU P0400698A2
Authority
HU
Hungary
Prior art keywords
modified
subject
polypeptides
receptor antagonist
reduced immunogenicity
Prior art date
Application number
HU0400698A
Other languages
English (en)
Inventor
Francis J. Carr
Graham Carter
Tim Jones
Stephen Williams.
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of HUP0400698A2 publication Critical patent/HUP0400698A2/hu
Publication of HUP0400698A3 publication Critical patent/HUP0400698A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/20—Protein or domain folding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

A találmány tárgyát olyan polipeptidek képezik, amelyek - elsősorbanterápiás célból - speciálisan embereknek adagolhatók. A találmányszerinti polipeptidek módosított polipeptidek, mely módosításeredményeként a polipeptid - embereknek történő adagolása esetén -kevésbé hajlamos immunreakció kiváltására. Közelebbről, a találmánytárgyát humán interleukin 1-receptort-antagonista (IL-1RA) módosítottváltozatai képezik, mely IL-1RA-proteinváltozatok in vivoalkalmazáskor lényegében nem immunogének vagy kevésbé immunogének,mint a megfelelő, módosítás nélküli alakjuk. Szintén a találmánytárgyát képezik a nem módosított proteinből származó T-sejtepitóppeptidek, valamint azok alkalmazása csökkent immunogenitású,módosított IL-1RA-változatok előállítására. A találmány tárgyátképezik továbbá a találmány szerinti módosított IL-1RA-molekulákatkódoló DNS-ek, a találmány szerinti módosított IL-1RA-molekulákattartalmazó gyógyászati készítmények, valamint eljárások a módosítottIL-1 RA-molekulák előállítására. Ó
HU0400698A 2001-02-06 2002-02-05 Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity HUP0400698A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01102573 2001-02-06
EP01103954 2001-02-19
PCT/EP2002/001170 WO2002062375A1 (en) 2001-02-06 2002-02-05 Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity

Publications (2)

Publication Number Publication Date
HUP0400698A2 true HUP0400698A2 (hu) 2004-06-28
HUP0400698A3 HUP0400698A3 (en) 2006-01-30

Family

ID=26076457

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400698A HUP0400698A3 (en) 2001-02-06 2002-02-05 Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity

Country Status (12)

Country Link
US (1) US20040076991A1 (hu)
EP (1) EP1357934A1 (hu)
JP (1) JP2004519230A (hu)
KR (1) KR20030074790A (hu)
CN (1) CN1549723A (hu)
BR (1) BR0207014A (hu)
CA (1) CA2437214A1 (hu)
HU (1) HUP0400698A3 (hu)
MX (1) MXPA03007004A (hu)
PL (1) PL362412A1 (hu)
RU (1) RU2003125640A (hu)
WO (1) WO2002062375A1 (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1638993A4 (en) * 2003-06-10 2007-05-09 Univ Melbourne IMMUNOMODULATING COMPOSITIONS, APPLICATIONS THEREOF AND METHOD FOR THE PRODUCTION THEREOF
HUE040595T2 (hu) * 2004-04-02 2019-03-28 Swedish Orphan Biovitrum Ab Publ Eljárás IL-1ra aggregációjának csökkentésére
GB0708376D0 (en) 2007-05-01 2007-06-06 Alligator Bioscience Ab Novel polypeptides and uses thereof
JP2010530895A (ja) * 2007-06-21 2010-09-16 アンジェリカ セラピューティックス，インク． 修飾毒素
WO2009110944A1 (en) * 2008-02-29 2009-09-11 Angelica Therapeutics, Inc. Modified toxins
CN103221422B (zh) 2010-07-29 2017-03-29 十一生物治疗股份有限公司 嵌合il‑1受体i型激动剂和拮抗剂
US9359405B2 (en) * 2011-03-14 2016-06-07 Phlogo Aps Antagonists of the interleukin-1 receptor
JP6234446B2 (ja) 2012-06-08 2017-11-22 アルカーメス，インコーポレイテッド ムチンドメインポリペプチドに連結された活性タンパク質を含む融合ポリペプチド
EP2968468B1 (en) 2013-03-13 2021-07-14 Buzzard Pharmaceuticals AB Chimeric cytokine formulations for ocular delivery
WO2014150600A2 (en) 2013-03-15 2014-09-25 Angelica Therapeutics, Inc. Modified toxins
AU2017313844B2 (en) 2016-08-19 2023-10-12 University Of Florida Research Foundation, Incorporated Methods and compositions for treating conditions using recombinant self-complementary adeno-associated virus
US11958886B2 (en) 2016-12-07 2024-04-16 University Of Florida Research Foundation, Incorporated IL-1RA cDNAs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7683391A (en) * 1990-04-27 1991-11-27 Upjohn Company, The Modified interleukin-1 inhibitors
WO1995010298A1 (en) * 1993-10-12 1995-04-20 Mary Lake Polan Method of contraception
IT1269989B (it) * 1994-09-21 1997-04-16 Dompe Spa Antagonisti recettoriali di il-1 ad aumentata attivita' inibitoria
JP2002512624A (ja) * 1997-05-21 2002-04-23 バイオベーション リミテッド 非免疫原性タンパク質の製造方法
EP1051432B1 (en) * 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
CA2395417A1 (en) * 1999-12-10 2001-06-14 Amgen Inc. Interleukin-1 receptor antagonist-related molecules and uses thereof

Also Published As

Publication number Publication date
HUP0400698A3 (en) 2006-01-30
EP1357934A1 (en) 2003-11-05
KR20030074790A (ko) 2003-09-19
RU2003125640A (ru) 2005-03-10
CN1549723A (zh) 2004-11-24
MXPA03007004A (es) 2003-11-18
PL362412A1 (en) 2004-11-02
CA2437214A1 (en) 2002-08-15
WO2002062375A1 (en) 2002-08-15
BR0207014A (pt) 2004-02-25
US20040076991A1 (en) 2004-04-22
JP2004519230A (ja) 2004-07-02

Similar Documents

Publication Publication Date Title
HUP0401534A2 (hu) Módosított humán IX. faktor
HUP0400700A2 (hu) Csökkentett immunogenitású, módosított humán agyi eredetű neutróf faktor (BDNF)
HUP0400698A2 (hu) Csökkentett immunogenitású módosított interleukin-1-receptor-antagonista (IL-1RA)
IL138424A (en) Covalently reactive antigen analogs and pharmaceutical compositions containing the same
HUP0402071A2 (hu) Csökkentett immunogenitású, módosított leptin
HUP0400703A2 (hu) Csökkentett immunogenitású módosított eritropoietin (EPO)
HUP0303534A2 (hu) Csökkent immunogenitású módosított interferon-béta
DK1151102T3 (da) Glycosylerede leptinpræparater og relaterede fremgangsmåder
HUP0102479A2 (hu) Neisseria meningitidis-ből származó BASBO29-polinukleotid(ok) és polipeptidek
UA91820C2 (ru) Терапевтическое применение вариантов хемокинов
HUP0303430A2 (hu) Csökkentett immunogenitású, módosított protamin
WO2004037175A3 (en) Compositions and methods for treating human papillomavirus-mediated disease
HUP0303309A2 (hu) Csökkentett immunogenitású módosított interferon-alfa
HUP0402334A2 (hu) Módosított humán növekedési hormon
DK1173476T3 (da) Funktionelle sojabönneproteiner
HUP0401121A2 (hu) Csökkentett immunogenitású, módosított trombopoietin (TPO)
HUP0303150A2 (hu) Csökkentett immunogenitású, módosított keratinocita növekedési faktor (KGF)
HUP0303310A2 (hu) Csökkentett immunogenitású módosított ciliáris neurotrofikus faktor (CNTF)
HUP0302566A2 (hu) Készítmények és eljárások emlőrák gyógykezelésére és diagnosztizálására
HUP0402041A2 (hu) Csökkentett immunogenitású, módosított granulocita-kolonizációt stimuláló faktor (G-CSF)
HUP0400340A2 (hu) Polipeptidek immunogenitásának csökkentésére szolgáló eljárások
HUP0303523A2 (hu) Csökkentett immunogenitású, módosított inzulin
WO2003093298A3 (en) Immunogenic peptides
HUP0402160A2 (hu) T-sejt-epitópok a karboxipeptidáz-G2-ben
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees